Table 2.
Treatment-related clinical adverse events
| Adverse event | TCH (N=39) | XEC-XT (N=33) | FEC-T (N=32) | TEC (N=35) | P-value |
|---|---|---|---|---|---|
| 3–4 grade leukopenia | 13 (33.3%) | 12 (36.7%) | 8 (25.0%) | 19 (54.3%) | 0.311 |
| 3/4 grade nausea, vomiting, and diarrhea | 7 (17.9%) | 8 (18.2%) | 5 (15.6%) | 8 (28.6%) | 0.554 |
| Hand-foot syndrome | 5 (12.5%) | 18 (54.5%) | 6 (18.8%) | 6 (17.1%) | <0.001 |
| Arthralgia and myalgia | 1(2.6%) | 2 (6.1%) | 1 (3.1%) | 2 (5.7%) | 0.847 |
| Alopecia | 31 (79.5%) | 23 (72.7%) | 25 (78.1%) | 28 (80.0%) | 0.884 |
| Decreased cardiac function | 0 | 0 | 0 | 0 | 1 |
Notes: P-value by chi-squared test or Fisher’s exact test when the cell expectation was less than six. Decreased cardiac function is defined as an EF value of less than 50% in color Doppler echocardiography.
Abbreviations: FEC-T, 5-fluorouracil/epirubicin/cyclophosphamide follow by docetaxel; TCH, docetaxel, carboplatin and trastuzumab; TEC, docetaxel, epirubicin and cyclophosphamide; XEC-XT, capecitabine/epirubicin/cyclophosphamide follow by capecitabine/docetaxel; EF, left ventricular ejection fraction.